Amneal Pharmaceuticals (AMRX) Q2 2024 earnings summary

Executive summary

• Q2 2024 net revenue rose 17% year-over-year to $702M, with broad-based growth across Generics, Specialty, and AvKARE segments.

• Adjusted EBITDA increased 11% to $162M, while GAAP net income fell to $6M due to higher costs and opioid litigation charges.

• CREXONT® (IPX203) received FDA approval for Parkinson's disease, with U.S. launch planned for September and expected peak sales of $300M–$500M.

• Full-year 2024 guidance was raised for revenue, adjusted EBITDA, and operating cash flow.

• Net leverage improved to 4.4x, with continued deleveraging and debt reduction efforts.

Financial highlights

• Q2 2024 net revenue: $702M (+17.1% YoY); adjusted EBITDA: $162M (+11% YoY); adjusted diluted EPS: $0.16 (down from $0.19 YoY).

• Q2 2024 GAAP net income: $6M (down from $12M YoY); Q2 2024 gross margin: 35.6% (down from 36.7% YoY).

• H1 2024 net revenue: $1.36B (+17.7% YoY); adjusted EBITDA: $315M (+19.9% YoY).

• Operating cash flow for H1 2024: $122M (up from $10M YoY); cash and cash equivalents at June 30, 2024: $44M.

• Total debt at June 30, 2024: $2.4B.

Outlook and guidance

• 2024 net revenue guidance raised to $2.70–$2.80B (13%–17% growth); adjusted EBITDA guidance increased to $610M–$630M (9%–13% growth).

• Adjusted diluted EPS expected between $0.57 and $0.63; operating cash flow guidance raised to $280M–$320M.

• Capital expenditures for 2024 expected at $60–$70M.

• Net leverage targeted below 4x in 2025 and below 3x thereafter.

• Management believes liquidity sources are sufficient to fund operations and obligations over the next 12 months.